NCT06997965View on ClinicalTrials.gov

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

April 1, 2028

Conditions
Crohn Disease
Interventions
DRUG

Mirikizumab

Mirikizumab is an IL-23 antagonist.

Sponsors

Lead Sponsor

Alimentiv Inc.
All Listed Sponsors
lead

Alimentiv Inc.

OTHER

NCT06997965 - Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | Biotech Hunter | Biotech Hunter